July 7, 2009 - The U.S. Food and Drug Administration (FDA) has approved Hologic Inc.'s premarket approval (PMA) application for the Adiana permanent contraception system.

The Adiana system is designed to provide women a minimally-invasive, non-incision alternative to traditional, surgical means of permanent contraception. In January 2009, Hologic received CE marking approval for the Adiana system and commenced marketing and sales of this product in certain European countries.

During the Adiana procedure, a slender, flexible instrument is passed through the body’s natural openings to deliver a low level of radiofrequency (RF) energy to a small section of each fallopian tube. A tiny, soft insert, about the size of a grain of rice, is then placed in each fallopian tube in the location where the energy was applied. During the three months following the procedure, the patient continues to use
temporary birth control while new tissue grows in and around the Adiana inserts, eventually blocking the fallopian tubes. At three months, a special X-ray test (called a hysterosalpingogram or HSG) is performed
to confirm the fallopian tubes are completely blocked and the patient may begin relying on Adiana for permanent contraception.

The Adiana permanent contraception procedure is minimally invasive, requires no incisions and can be performed in the comfort of the doctor’s office using local anesthesia. Patients are normally able to return to work or resume their daily activities within one day. In contrast, traditional methods of permanent contraception, such as tubal ligation, require more invasive surgical procedures, usually are conducted in a hospital under general anesthesia and typically require four to five days of recovery. As a result, these more invasive surgical procedures can pose serious risk of complications, including anesthesia-related problems and damage to organs or blood vessels. There were approximately 70,000 female transcervical contraception procedures performed in the U.S. last year.1

For more information: www.hologic.com


Related Content

News | MRI Breast

July 2, 2026 – Quibim has announced the European and UK launch of QP-Breast, its CE and UKCA-marked AI tool which ...

Time July 02, 2026
arrow
News | Mammography

June 30, 2026 — The Food and Drug Administration has cleared new contrast-enhanced mammography (CEM) and CEM biopsy ...

Time June 30, 2026
arrow
News | Mammography

June 23, 2026 — Using artificial intelligence (AI), researchers found that image-based risk scores for breast cancer ...

Time June 24, 2026
arrow
Feature | X-Ray | Kyle Hardner

Water-window X-rays allow researchers to visualize biological cells at high contrast without staining agents or other ...

Time June 23, 2026
arrow
News | Radiology Imaging

June 15, 2026 — Lead Glass Pro, a supplier of radiation shielding products, has expanded its turnkey installation ...

Time June 18, 2026
arrow
News | Digital Radiography (DR)

June 3, 2026 – Konica Minolta Healthcare Americas has announced a new version of AeroRemote Insights, the company’s ...

Time June 05, 2026
arrow
News

May 21, 2026 – Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer ...

Time May 22, 2026
arrow
News | FDA

May 6, 2026 — Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer ...

Time May 07, 2026
arrow
News | Breast Imaging

April 15, 2026 — QT Imaging Holdings, Inc. has launched its QTI Imaging-Olea Viewer, developed in collaboration with ...

Time April 15, 2026
arrow
News | Breast Imaging

April 1, 2026 — QT Imaging Holdings has released its latest image reconstruction software update, version 4.5.0. This ...

Time April 02, 2026
arrow
Subscribe Now